23 April
2024
Avacta Group
plc
("Avacta"
or the "Company" and, together with its subsidiary undertakings,
the "Group")
Notice of
Results
Investor Presentation via
Investor Meet Company
Avacta Group plc (AIM: AVCT), a life
sciences company developing innovative, targeted oncology drugs and
powerful diagnostics, will announce its audited preliminary results
for year ended 31st December 2023 ("FY23") on
30th April 2024.
Alastair Smith, Chief Executive
Officer; Tony Gardiner, Chief Financial Officer; and Christina
Coughlin MD, PhD, Head of Research and Development, will also
deliver a live presentation via Investor Meet Company at 12:30 BST
on the day.
The presentation is open to all
existing and potential shareholders.
Investors can sign up to Investor
Meet Company for free and add to meet AVACTA GROUP PLC
via:
https://www.investormeetcompany.com/avacta-group-plc/register-investor.
Investors who already follow Avacta on the
Investor Meet Company platform will automatically be
invited.
Questions can be submitted pre-event
via the Investor Meet Company dashboard up until 29th
April 09:00 BST, or at any time during the live
presentation.
The Company will also post the
results presentation on its website at the following
page: https://avacta.com/investors/investor-resources/
-Ends-
For
further information from Avacta Group plc, please
contact:
|
Avacta Group plc
Alastair Smith, Chief Executive
Officer
Tony Gardiner, Chief Financial
Officer
Michael Vinegrad, Group
Communications Director
|
Tel: +44
(0) 1904 21 7070
www.avacta.com
|
|
Stifel Nicolaus Europe Limited (Nomad and Joint
Broker)
Nicholas Moore / Nick Adams / Samira
Essebiyea / Nick Harland / Ben Good
|
Tel: +44
(0) 207 710 7600
www.stifel.com
|
|
Peel Hunt (Joint Broker)
James Steel / Chris Golden / Patrick
Birkholm
|
Tel: +44
(0) 207 418 8900
www.peelhunt.com
|
|
ICR
Consilium (Media and IR)
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
|
avacta@consilium-comms.com
|
|
|
|
|
|
|
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based life
sciences company focused on improving healthcare outcomes through
targeted cancer treatments and diagnostics.
Avacta has two divisions focused on
therapeutics and diagnostics.
Avacta Therapeutics: a clinical
stage oncology biotech division harnessing proprietary therapeutic
platforms to develop novel, highly targeted cancer
drugs.
Avacta Diagnostics: focused on
supporting healthcare professionals and broadening access to
diagnostics.
Avacta has two proprietary
platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly
specific substrate for fibroblast activation protein (FAP) which is
upregulated in most solid tumours compared with healthy tissues.
The pre|CISION™ platform harnesses this tumour specific protease to
activate pre|CISION™ peptide drug conjugates and pre|CISION™
antibody/Affimer® drug conjugates in the tumour microenvironment,
reducing systemic exposure and toxicity, allowing dosing to be
optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme
AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase
1 studies. It has shown a dramatic improvement in safety and
tolerability in clinical trials to date compared with standard
doxorubicin and preliminary signs of clinical activity in multiple
patients.
To register for news alerts by email
go to https://avacta.com/investors/investor-news-email-alerts/